F-star Therapeutics, Inc.
FSTXDelisted Mar 9, 2023- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001566373
F-star Therapeutics, Inc. was delisted on Mar 9, 2023; its insiders filed their last Form 4 on Mar 9, 2023; 59 institutions reported holding it in 13F filings for Q4 2022, worth $57.8M in total; Fairfax Financial was the only superinvestor holding it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 1:32 PM ET
Revenue flow, Q3 FY2022
Where the revenue went in Q3 FY2022, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for Q3 FY2022: $18.4M (1636.2% of revenue).
Income statement
Each column is one quarter, newest first.
| Line item | Q3 FY2022 | Q2 FY2022 | Q1 FY2022 | Q4 FY2021† | Q3 FY2021 | Q2 FY2021 | Q1 FY2021 | Q4 FY2020† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | – | Aug 11, 2022 | May 10, 2022 | Mar 14, 2022 | Nov 10, 2021 | Aug 12, 2021 | May 17, 2021 | Mar 29, 2021 |
| Revenue | $1.13M | $0 | $2.55M | $17.5M† | $751.0K | $0 | $2.92M | – |
| Research and development | $9.67M | $8.72M | $8.04M | $8.21M† | $5.11M | $8.44M | $7.27M | $3.10M† |
| Selling, general and administrative | $5.16M | $7.46M | $5.70M | $4.96M† | $5.24M | $6.50M | $6.43M | $11.6M† |
| Operating income | -$13.7M | -$16.2M | -$11.2M | $4.32M† | -$9.60M | -$14.9M | -$10.8M | -$3.49M† |
| Interest expense | $378.0K | $334.0K | $308.0K | $775.0K† | – | – | – | – |
| Income tax | $0 | $0 | – | -$562.0K† | $0 | $82.0K | $108.0K | -$1.00K† |
| Net income | -$18.4M | -$19.0M | -$12.1M | $4.74M† | -$10.8M | -$15.6M | -$9.87M | -$5.54M† |
| EPS, basic | $-0.84 | $-0.88 | – | – | – | – | – | – |
| EPS, diluted | $-0.84 | $-0.88 | – | – | – | – | – | – |
| Weighted shares, basic | 21.9M | 21.6M | – | – | – | – | – | – |
| Weighted shares, diluted | 21.9M | 21.6M | – | – | – | – | – | – |
| Margins and growth | ||||||||
| Operating margin | -1218.3% | – | -438.6% | 24.7% | -1278.4% | – | -369.5% | – |
| Net margin | -1636.2% | – | -473.8% | 27.1% | -1436.9% | – | -338.3% | – |
| Revenue growth, year over year | +49.8% | – | −12.5% | – | – | – | – | – |
Balance sheet
Each column is one quarter, newest first.
| Line item | Q3 FY2022 | Q2 FY2022 | Q1 FY2022 | Q4 FY2021† | Q3 FY2021 | Q2 FY2021 | Q1 FY2021 | Q4 FY2020† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | – | Aug 11, 2022 | May 10, 2022 | Mar 14, 2022 | Nov 10, 2021 | Aug 12, 2021 | May 17, 2021 | Mar 29, 2021 |
| Cash and equivalents | $35.6M | $53.0M | $68.8M | $78.5M | $71.0M | $81.6M | $3.68M | $18.5M |
| Accounts receivable | – | – | – | – | – | – | $2.80M | – |
| Total current assets | $49.6M | $64.9M | $77.3M | $84.7M | $76.2M | $85.3M | $13.8M | $26.1M |
| Property, plant and equipment | $879.0K | $813.0K | $743.0K | $887.0K | $1.01M | $1.16M | $1.06M | $789.0K |
| Goodwill | $14.1M | $14.5M | $14.8M | $14.9M | $14.9M | $15.0M | $15.0M | $14.9M |
| Intangible assets | $16.2M | $17.3M | $18.4M | $18.8M | $18.8M | $19.2M | $19.2M | $19.0M |
| Total assets | $83.7M | $100.6M | $114.7M | $123.0M | $114.8M | $125.0M | $53.4M | $63.6M |
| Accounts payable | $2.50M | $4.05M | $4.31M | $3.08M | $1.57M | $2.43M | $4.08M | $4.60M |
| Short-term debt | $1.31M | $353.0K | – | – | – | – | – | $0 |
| Total current liabilities | $14.7M | $15.3M | $12.7M | $12.1M | $8.84M | $9.95M | $14.3M | $17.0M |
| Long-term debt | $8.53M | $9.40M | $9.68M | $9.61M | $9.54M | $9.47M | – | – |
| Total liabilities | $26.8M | $29.0M | $26.5M | $26.2M | $24.7M | $26.0M | $18.6M | $20.6M |
| Shareholders' equity | $56.9M | $71.6M | $88.2M | $96.9M | $90.1M | $99.0M | $34.8M | $43.0M |
Cash flow statement
Each column is one quarter, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | Q3 FY2022† | Q2 FY2022† | Q1 FY2022 | Q4 FY2021† | Q3 FY2021† | Q2 FY2021† | Q1 FY2021 | Q4 FY2020† |
|---|---|---|---|---|---|---|---|---|
| Period end | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 |
| Filing | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K |
| Reported | – | Aug 11, 2022 | May 10, 2022 | Mar 14, 2022 | Nov 10, 2021 | Aug 12, 2021 | May 17, 2021 | Mar 29, 2021 |
| Operating cash flow | -$16.5M† | -$16.5M† | -$11.6M | $6.78M† | -$10.7M† | -$8.96M† | -$14.4M | -$496.0K† |
| Capital expenditures | $47.0K† | – | – | $0† | $0† | $391.0K† | $267.0K | – |
| Free cash flow | -$16.6M | – | – | $6.78M | -$10.7M | -$9.35M | -$14.6M | – |
| Stock-based compensation | $1.45M† | $1.42M† | $1.45M | $1.34M† | $1.51M† | $1.86M† | $2.18M | $1.75M† |
| Investing cash flow | $1.00K† | – | – | $0† | $0† | -$391.0K† | -$252.0K | -$2.18M† |
| Financing cash flow | $5.00K† | $303.0K† | $1.88M | $1.05M† | $2.00K† | $87.0M† | $0 | $35.3M† |
| Net change in cash | -$16.5M† | -$16.6M† | -$9.74M | $7.83M† | -$10.7M† | $77.7M† | -$14.6M | $32.6M† |
| Ratio | ||||||||
| Stock-based compensation, % of revenue | 128.5% | – | 57.0% | 7.7% | 201.7% | – | 74.7% | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Sep 30, 2022 | 22.0M | +6.6% | SEC |
| Jun 30, 2022 | 21.6M | +4.7% | SEC |
| Mar 31, 2022 | 21.5M | +136.2% | SEC |
| Mar 1, 2022 | 21.1M | +131.5% | SEC |
| Nov 8, 2021 | 20.6M | +19.4% | SEC |
| Aug 7, 2021 | 20.6M | +19.5% | SEC |
| May 12, 2021 | 19.4M | +13.3% | SEC |
| Mar 24, 2021 | 9.10M | −46.8% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- Values marked † are derived: Q4 is the full year minus the first three quarters, single-quarter cash flows are year-to-date figures minus the previous year-to-date figures, and the Q4 balance sheet is the year-end balance sheet.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.